Independent Research set a €66.00 ($76.74) price objective on Gerresheimer (ETR:GXI) in a research report sent to investors on Thursday morning. The brokerage currently has a neutral rating on the stock.
A number of other equities analysts also recently commented on GXI. Berenberg Bank set a €81.00 ($94.19) target price on shares of Gerresheimer and gave the company a buy rating in a research note on Friday, November 23rd. JPMorgan Chase & Co. set a €49.50 ($57.56) target price on shares of Gerresheimer and gave the company a sell rating in a research note on Wednesday, January 2nd. Deutsche Bank set a €86.00 ($100.00) target price on shares of Gerresheimer and gave the company a buy rating in a research note on Tuesday, January 15th. Credit Suisse Group set a €82.00 ($95.35) target price on shares of Gerresheimer and gave the company a buy rating in a research note on Tuesday, February 5th. Finally, Goldman Sachs Group set a €65.00 ($75.58) target price on shares of Gerresheimer and gave the company a neutral rating in a research note on Monday, February 11th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of €68.23 ($79.33).
Shares of GXI stock opened at €62.20 ($72.33) on Thursday. Gerresheimer has a 52 week low of €59.97 ($69.73) and a 52 week high of €78.25 ($90.99).
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
Read More: Diversification For Individual Investors
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.